Stock Ratings / Health Care / TVRD / insiders

CLRB (37) GTBP (46) ASBP (33) CALC (47) ⌘ Pro Terminal →

Tvardi Therapeutics Inc. (TVRD) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are TVRD insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies TVRD leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$0.86 -2.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Tvardi Therapeutics Inc. (TVRD) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $11.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TVRD)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

TVRD Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (TVRD)

No recent open-market Form 4 cluster sales or emergency dumps flagged on TVRD. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TVRD)

✓Walkthrough of TVRD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TVRD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -72.70%⚡ TESTING RESISTANCE

2026-10-30O $0.87H $0.93L $0.77C $0.86VOL 154.9K

RES: $1.10SUP: $0.30SMA50: $1.38SMA200: $2.76

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TVRD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TVRD Butterfly Map → + Track TVRD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TVRD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TVRD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TVRD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TVRD)

Health Care Rank #652 of 1016 ⚔️ CLRB vs TVRD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TVRD vs. CLRB, GTBP, ASBP, CALC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Tvardi Therapeutics Inc. (TVRD) ranks #652 by composite RQD confidence (40/100, grade D-) and #884 by equity capitalization ($11.5M). Within this direct 5-issuer industry benchmark cohort, TVRD leads on earnings valuation at N/A trailing P/E, while TVRD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CALC currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with TVRD at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TVRD ACTIVE Tvardi Therapeutics Inc.	D-	40/100	—	—	-35.0%	-2.73%	$11.5M	Benchmark Subject
CLRB Cellectar Biosciences Inc.	D-	37/100	—	—	-35.0%	-1.61%	$11.5M	/clrb-vs-tvrd →
GTBP GT Biopharma Inc.	D	46/100	—	—	-35.0%	+1.63%	$11.5M	/gtbp-vs-tvrd →
ASBP Aspire-Lakewood Holdings Inc.	E	33/100	—	-1.9%	-35.0%	-4.50%	$11.9M	/asbp-vs-tvrd →
CALC CalciMedica Inc.	D	47/100	—	—	-35.0%	+5.42%	$11.9M	/calc-vs-tvrd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001346830

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tvardi Therapeutics Inc. (TVRD) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $7.1M , and -100.0% cumulative change since FY2023) , GAAP net income of -$18.2M, operating cash flow of -$23.5M, and free cash flow of -$23.5M (-21.4% YoY). On the balance sheet, TVRD closed FY2025 with $32.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$18.2M	-$23.5M	-$23.5M	$32.1M	—
FY2024 (FY)	2024-12-31	$7.1M	-$29.4M	-$18.3M	-$19.4M	$35.2M	—
FY2023 (FY)	2023-12-31	$21.0M	-$11.8M	-$92.1M	-$92.1M	—	—

3. TVRD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TVRD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Tvardi Therapeutics Inc. (NASDAQ: TVRD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.86 (-2.73% 1D, market cap $11.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TVRD ranks #652 in composite RQD confidence.

How does TVRD compare to CLRB and GTBP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TVRD carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLRB (Cellectar Biosciences Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $11.5M) and GTBP (GT Biopharma Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $11.5M). Among the 5-stock peer group, TVRD leads on earnings multiple (N/A) while TVRD leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TVRD?

Per TVRD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001346830), Tvardi Therapeutics Inc. generated $0 in revenue (-100.0% YoY), -$18.2M in net income, and -$23.5M in free cash flow against $32.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TVRD trading relative to its 50-day, 200-day, and 52-week technical levels?

TVRD last traded at $0.86 (-2.73% on volume of 111,919 shares), positioning the stock -37.68% below its 50-day simple moving average ($1.38) and -68.84% below its 200-day simple moving average ($2.76). Across its 52-week range of $0.77 to $5.69, TVRD sits at the 1.8% percentile with a 14-day RSI of 27.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.97).

TVRD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are TVRD insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies TVRD leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: TVRD RQD Cockpit TVRD 12M Forecast TVRD Earnings & Move TVRD Dividends & DRIP TVRD Insiders & 13F TVRD Whale Options TVRD Profit Sankey TVRD News & Why